Search Follow us
Sparks Team
12 September 2019 · 2 min read

Standard Life Private Equity Trust (SLPE); declares 3.2p per share dividend

Shareholders have the option of participating in the company’s dividend reinvestment plan (DRIP)

Standard Life Private Equity announced a third-quarter dividend of 3.2p per ordinary share in respect of the year ending 30 September 2019. The ex-dividend date is 19 September 2019.

Read more...
Sparks Team
12 September 2019 · 2 min read

Silence Therapeutics (SLN); posts loss after tax of £8.2m in H1 2019

Silence Therapeutics announced its unaudited interim results for the half year to 30 June 2019. Net cash outflow from operating activities was £10.3m (H1 2018: £8.8m), while cash and cash equivalents and term deposits stood at £16.5m (FY 2018: £26.5m). Research and development expenses decreased by £0.1m to £5.1m.

Read more...
11 September 2019

Apple (AAPL); offer detail on Arcade service

Apple has offered more details on its upcoming cross-platform subscription service Apple Arcade, detailing some of the exclusive games due out for the service as well as its cost early on in today’s big Apple announcement.

Read more...
Sparks Team
11 September 2019

Epwin Group (EPWN); revenue in line with expectations at £140.0m

Basic EPS and PBT stood at 3.78p and £6.7m, respectively

Epwin Group announced its half-year results for the six months to 30 June 2019. Underlying operating profit increased 25.3% to £9.4m on a reported basis, while revenues were up 0.5% on a like-for-like basis, against strong H1 2018 comparatives.

Read more...
Sparks Team
11 September 2019 · 2 min read

Serco Group (SRP); Australian immigration services contract extended

The contract further allows for a second extension of up to two years from 10 December 2021

Serco Group announced that its contract for the provision of onshore immigration detention facilities and detainee services for Australian states and territories has now been extended by two years to 10 December 2021. The Australian government’s Department of Home Affairs (the Department) has notified the company of this extension.

Read more...
Sparks Team
11 September 2019 · 2 min read

Chemring Group (CHG); reports order book of £480m

The board's current expectations for the year ending 31 October 2019 remained unchanged

Chemring issued a trading update for the period ending 10 September 2019. Trading was on track and the company expects the phasing of trading in FY19 to result in a weighting of operating cash generation to the final quarter.

Read more...
11 September 2019

Allied Minds (ALM); confirms for initial deployment of its CBRS technology

Federated has a customer base of more than 25 companies

Following on swiftly from Federated Wireless’ $51m Series C fund raising announced on 4 September 2019, Allied Minds has confirmed that Federated Wireless has now received Federal Communications Commission (FCC) approval for Initial Commercial Deployment (ICD) of its CBRS technology, its key milestone for 2019.

Read more...
Fiona Orford-Williams
10 September 2019 · 2 min read

Euromoney (ERM); carry out strategic review

Euromoney has carries out a strategic review of its Asset Management business. The division accounted for 39% of FY18 revenues and 44% of FY18 operating profit before central costs. It has been under structural and cyclical pressure as its clients (primarily sell-side providers) have struggled with the dual impacts of MiFID2 and the growth of passive asset management. A sale is not necessarily the only outcome of the review and, if that is the route chosen, management has a record of strong discipline in M&A pricing.

Read more...
Sparks Team
10 September 2019 · 2 min read

Angle (AGL); announces research with Parsortix in prostate cancer

ANGLE announced that Queen Mary University of London’s Barts Cancer Institute has published results of new work undertaken in early stage prostate cancer utilising ANGLE’s Parsortix system. According to the company, the results demonstrate the potential to outperform current standard of care in the detection and assessment of prostate cancer. This results build on Barts Cancer Institute’s previous work with the Parsortix system in later stage prostate cancer and assessment of aggressiveness.

Read more...
Sparks Team
10 September 2019 · 3 min read

Boku Inc (BOKU); revenue up 39% to $23.5m for H1 2019

The company expects a strong second half within payments

Boku announced its unaudited half-year results for the period ended 30 June 2019. Gross profit margin at group level stood at 87.5% for the period. Gross margins across payments and identity performed well at 95% and 43%, respectively. The company’s cash balance stood at $27.9m as of 30 June 2019.

Read more...